Oslo, Norway, July 4, 2022 â€“ Nykode Therapeutics ASA (Oslo Stock Exchange (OSE): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced that 200,000 share options have been granted to Klaus Edvardsen in connection with his appointment as Chief Development Officer. The share options will have a strike price of NOK 31.11 per share, have a five-year term and will vest equally over a four-year vesting period.
 
Please see further details in attached document.